INTRASENSE SAS (ALINS.PA) Stock Fundamental Analysis
Europe - EPA:ALINS - FR0011179886 - Common Stock
0.264 EUR
0 (0%)
Taking everything into account, ALINS scores 1 out of 10 in our fundamental rating. ALINS was compared to 10 industry peers in the Health Care Technology industry. Both the profitability and financial health of ALINS have multiple concerns. While showing a medium growth rate, ALINS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ALINS had negative earnings in the past year.
In the past year ALINS has reported a negative cash flow from operations.
In the past 5 years ALINS always reported negative net income.
In the past 5 years ALINS always reported negative operating cash flow.
1.2 Ratios
ALINS has a Return On Assets of -73.59%. This is amonst the worse of the industry: ALINS underperforms 80.00% of its industry peers.
ALINS has a Return On Equity of -341.90%. This is amonst the worse of the industry: ALINS underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.59% | ||
| ROE | -341.9% | ||
| ROIC | N/A |
ROA(3y)-53.46%
ROA(5y)-37.03%
ROE(3y)-186.99%
ROE(5y)-123.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALINS has a worse Gross Margin (69.46%) than 60.00% of its industry peers.
In the last couple of years the Gross Margin of ALINS has declined.
The Profit Margin and Operating Margin are not available for ALINS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-4.31%
2. Health
2.1 Basic Checks
ALINS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALINS has been increased compared to 1 year ago.
ALINS has more shares outstanding than it did 5 years ago.
ALINS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.32, we must say that ALINS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ALINS (-1.32) is worse than 70.00% of its industry peers.
ALINS has a Debt/Equity ratio of 0.54. This is a neutral value indicating ALINS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.54, ALINS is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.32 |
ROIC/WACCN/A
WACC7.73%
2.3 Liquidity
ALINS has a Current Ratio of 0.48. This is a bad value and indicates that ALINS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.48, ALINS is doing worse than 80.00% of the companies in the same industry.
ALINS has a Quick Ratio of 0.48. This is a bad value and indicates that ALINS is not financially healthy enough and could expect problems in meeting its short term obligations.
ALINS has a worse Quick ratio (0.48) than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.48 |
3. Growth
3.1 Past
The earnings per share for ALINS have decreased strongly by -63.91% in the last year.
ALINS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.56%.
ALINS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.51% yearly.
EPS 1Y (TTM)-63.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.79%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-18.74%
Revenue growth 5Y-7.51%
Sales Q2Q%33.25%
3.2 Future
The Earnings Per Share is expected to grow by 27.48% on average over the next years. This is a very strong growth
ALINS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 49.68% yearly.
EPS Next Y37.5%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year71.49%
Revenue Next 2Y49.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ALINS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALINS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALINS's earnings are expected to grow with 27.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALINS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALINS (10/31/2025, 7:00:00 PM)
0.264
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.89%
Ins Owner ChangeN/A
Market Cap13.92M
Revenue(TTM)2.65M
Net Income(TTM)-5655000
Analysts40
Price Target0.24 (-9.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.41 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.04
BVpS0.03
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.59% | ||
| ROE | -341.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.46% | ||
| FCFM | N/A |
ROA(3y)-53.46%
ROA(5y)-37.03%
ROE(3y)-186.99%
ROE(5y)-123.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-4.31%
F-Score1
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 169.4% | ||
| Cap/Sales | 98.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.48 | ||
| Altman-Z | -1.32 |
F-Score1
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)186.16%
Cap/Depr(5y)148.72%
Cap/Sales(3y)65.28%
Cap/Sales(5y)45.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-63.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.79%
EPS Next Y37.5%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-18.74%
Revenue growth 5Y-7.51%
Sales Q2Q%33.25%
Revenue Next Year71.49%
Revenue Next 2Y49.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-59.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.37%
OCF growth 3YN/A
OCF growth 5YN/A
INTRASENSE SAS / ALINS.PA FAQ
Can you provide the ChartMill fundamental rating for INTRASENSE SAS?
ChartMill assigns a fundamental rating of 1 / 10 to ALINS.PA.
What is the valuation status of INTRASENSE SAS (ALINS.PA) stock?
ChartMill assigns a valuation rating of 1 / 10 to INTRASENSE SAS (ALINS.PA). This can be considered as Overvalued.
What is the profitability of ALINS stock?
INTRASENSE SAS (ALINS.PA) has a profitability rating of 0 / 10.
What is the financial health of INTRASENSE SAS (ALINS.PA) stock?
The financial health rating of INTRASENSE SAS (ALINS.PA) is 0 / 10.
What is the earnings growth outlook for INTRASENSE SAS?
The Earnings per Share (EPS) of INTRASENSE SAS (ALINS.PA) is expected to grow by 37.5% in the next year.